Neovasc Inc. Net Debt

Net Debt of NVCN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Debt growth rates and interactive chart. Net debt is the sum of all interest-bearing debt (short-term and long-term) minus cash and short-term investments. A positive number indicates the company's total debt exceeds its cash and short-term investments balances, while a negative number means the company has more cash than its total debt. This figure is also used in Enterprise value calculation.


Highlights and Quick Summary

  • Net Debt for the quarter ending March 31, 2022 was $-32.1 Million (a -24.12% decrease compared to previous quarter)
  • Year-over-year quarterly Net Debt decreased by -40.28%
  • Annual Net Debt for 2021 was $-42.3 Million (a 886.59% increase from previous year)
  • Annual Net Debt for 2020 was $-4.29 Million (a -141.87% decrease from previous year)
  • Annual Net Debt for 2019 was $10.3 Million (a 89.94% increase from previous year)
Visit stockrow.com/NVCN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Debt of Neovasc Inc.

Most recent Net Debtof NVCN including historical data for past 10 years.

Interactive Chart of Net Debt of Neovasc Inc.

Neovasc Inc. Net Debt for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-32.13
2021 $-42.35 $-46.67 $-53.8 $-60.55 $-42.35
2020 $-4.29 $-5.28 $0.89 $3.2 $-4.29
2019 $9.37 $5.73 $-0.33 $-0.86 $10.25
2018 $5.37 $14.03 $4.11 $15.13 $5.4
2017 $2.5 $-76.59 $-81.77 $-86.28 $2.51
2016 $-92.95 $33.72 $-46.9 $-92.95
2015 $-55.03 $-64.38 $-76.25 $-81.78 $-55.03
2014 $-15.36 $-19.81 $-23.34 $-24.5 $-15.36
2013 $-3.07 $-3.77 $-5.09 $-4.56 $-3.07
2012 $-5.58 $-1.74 $-2.3 $-2.87 $-5.58
2011 $-3.58 $-3.58

Business Profile of Neovasc Inc.

Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.